CN111566229A - 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用 - Google Patents

乳腺癌分子分型及远处转移风险基因群及诊断产品和应用 Download PDF

Info

Publication number
CN111566229A
CN111566229A CN201980006647.6A CN201980006647A CN111566229A CN 111566229 A CN111566229 A CN 111566229A CN 201980006647 A CN201980006647 A CN 201980006647A CN 111566229 A CN111566229 A CN 111566229A
Authority
CN
China
Prior art keywords
gene
breast cancer
risk
distant metastasis
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980006647.6A
Other languages
English (en)
Other versions
CN111566229B (zh
Inventor
周彤
胡志元
周伟庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Shanzhun Biotechnology Co ltd
Original Assignee
Shanghai Shanzhun Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Shanzhun Biotechnology Co ltd filed Critical Shanghai Shanzhun Biotechnology Co ltd
Publication of CN111566229A publication Critical patent/CN111566229A/zh
Application granted granted Critical
Publication of CN111566229B publication Critical patent/CN111566229B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了乳腺癌亚型分型及评估远处转移风险基因群及其体外诊断产品和应用。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980006647.6A 2018-09-30 2019-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用 Active CN111566229B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811166148.7A CN110964815A (zh) 2018-09-30 2018-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用
CN2018111661487 2018-09-30
PCT/CN2019/109459 WO2020064006A2 (zh) 2018-09-30 2019-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用

Publications (2)

Publication Number Publication Date
CN111566229A true CN111566229A (zh) 2020-08-21
CN111566229B CN111566229B (zh) 2021-03-26

Family

ID=69950303

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811166148.7A Pending CN110964815A (zh) 2018-09-30 2018-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用
CN201980006647.6A Active CN111566229B (zh) 2018-09-30 2019-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811166148.7A Pending CN110964815A (zh) 2018-09-30 2018-09-30 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用

Country Status (2)

Country Link
CN (2) CN110964815A (zh)
WO (1) WO2020064006A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102586410A (zh) * 2011-01-18 2012-07-18 苏州科贝生物技术有限公司 一种定量评估乳腺癌远期复发风险的试剂盒
WO2014186349A1 (en) * 2013-05-13 2014-11-20 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
CN104293910A (zh) * 2014-07-23 2015-01-21 周彤 一组评估乳腺癌分子分型基因群及其检测试剂盒
CN104878086A (zh) * 2009-02-11 2015-09-02 卡里斯Mpi公司 肿瘤的分子谱分析
CN105849278A (zh) * 2014-01-08 2016-08-10 李铮 基于唾液糖蛋白糖链鉴别肝系列病的凝集素芯片及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104878086A (zh) * 2009-02-11 2015-09-02 卡里斯Mpi公司 肿瘤的分子谱分析
CN102586410A (zh) * 2011-01-18 2012-07-18 苏州科贝生物技术有限公司 一种定量评估乳腺癌远期复发风险的试剂盒
WO2014186349A1 (en) * 2013-05-13 2014-11-20 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
CN105849278A (zh) * 2014-01-08 2016-08-10 李铮 基于唾液糖蛋白糖链鉴别肝系列病的凝集素芯片及其应用
CN104293910A (zh) * 2014-07-23 2015-01-21 周彤 一组评估乳腺癌分子分型基因群及其检测试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAN,N.N. 等: "Distinct expression of CDCA3,CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient", 《ONCOTARGET》 *

Also Published As

Publication number Publication date
WO2020064006A2 (zh) 2020-04-02
CN111566229B (zh) 2021-03-26
WO2020064006A3 (zh) 2020-04-30
CN110964815A (zh) 2020-04-07

Similar Documents

Publication Publication Date Title
EP2504451B1 (en) Methods to predict clinical outcome of cancer
WO2018001295A1 (zh) 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN114341367B (zh) 肺腺癌分子分型及生存风险基因群及诊断产品和应用
WO2021036620A1 (zh) 一组卵巢癌预后相关基因的应用
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
WO2022135552A1 (zh) 结直肠癌分子分型及生存风险基因群及诊断产品和应用
CN113981083B (zh) 用于结直肠癌基因甲基化检测的核酸组合、试剂盒
CN111534588A (zh) 基于荧光定量pcr检测急性淋巴细胞白血病中基因突变的试剂盒及方法
US20220205043A1 (en) Detecting cancer risk
CN111566229B (zh) 乳腺癌分子分型及远处转移风险基因群及诊断产品和应用
CN115482935B (zh) 预测小细胞转化的肺腺癌患者预后模型及其建立方法
CN108456730B (zh) 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用
WO2021175236A1 (zh) 干扰素信号通路相关基因群及诊断产品和应用
WO2015127103A1 (en) Methods for treating hepatocellular carcinoma
US20220389513A1 (en) A Method of Estimating a Circulating Tumor DNA Burden and Related Kits and Methods
EP4277999A1 (en) Methods for evaluation of early stage oral squamous cell carcinoma
EP4168591A1 (en) Methods for detecting and predicting cancer
WO2012045019A2 (en) Brca deficiency and methods of use
WO2017106365A1 (en) Methods for measuring mutation load
US20140024028A1 (en) Brca deficiency and methods of use
CN115851927A (zh) 肺鳞癌分子分型及生存风险基因群及诊断产品和应用
CN116287247A (zh) 线粒体凋亡相关基因多态性在急性髓系白血病蒽环类化疗反应和易感性预测中的应用
WO2023066972A1 (en) Dna methylation signature for diagnosing hepatocellular carcinoma
CN117265117A (zh) 一种新型tRF分子标记物CAT1及其在制备用于癌症诊断和预后试剂盒中的应用
CN115873944A (zh) 一种基于stk32b基因的胶质母细胞瘤辅助诊断、预后评价的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant